Geistlich Pharma AG, a worldwide leader in regenerative technologies, announced an exclusive national distribution partnership agreement with StimLabs of Roswell, GA. StimLabs will assume all commercial activities for Geistlich’s Advanced Wound Matrix (Derma-Gide®) effective immediately, offering a leading and clinically proven solution for acute and chronic wounds.
“Geistlich is very pleased to have StimLabs as an exclusive distribution partner of Derma-Gide in the United States and is looking forward to supporting our joint success moving forward,” said Diego Gabathuler, CEO of Geistlich. “With Derma-Gide, now listed as covered in the recently published U.S. Centers for Medicare & Medicaid Services’ (CMS) Local Coverage Determination (LCD) for diabetic foot ulcers (DFUs), StimLabs will leverage their national channel to support clinicians in the adoption and utilization of this highly differentiated technology. And we are excited to offer our Advanced Wound Matrix to patients suffering from difficult to heal wounds.”
Derma-Gide Advanced Wound Matrix is an innovative and 510k cleared porcine derived solution, processed using proprietary technologies, and is indicated for the management of wounds. Its unique design characteristics support wound healing and provide ease of use and handling for health care providers.
StimLabs CEO John Daniel commented on the agreement, “We look forward to working with Geistlich, a trusted global leader in regenerative technologies and are pleased to add a high quality, clinically proven xenograft option to our portfolio.”
